Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tissue Degeneration Clear all
Completed Phase 3 Interventional Results available

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

NCT03805100
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Biological
Lead sponsor
Xbrane Biopharma AB
Industry
Eligibility
50 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

NCT04894071
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
QA102, Placebo
Drug
Lead sponsor
Smilebiotek Zhuhai Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 26, 2026, 4:14 PM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

NCT01624636
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Placebo, LFG316
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 26, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Results available

Clinical Outcomes of the Trinica(R) Anterior Lumbar Plate: Fixed Screws vs. Variable Screws

NCT00762723
View directory record Official record
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Interventions
Trinica Anterior Lumbar Plate System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Daphne, Alabama • Mobile, Alabama • San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 26, 2026, 4:14 PM EDT
Not listed Phase 4 Interventional

Post Intravitreal Injection Topical NSAID vs. Patching

NCT03918590
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching
Drug · Other
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 26, 2026, 4:14 PM EDT
Not listed Phase 2Phase 3 Interventional

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

NCT06229665
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda Light Delivery System
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 26, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss

NCT07577219
View directory record Official record
Conditions
Low Vision, Central Visual Impairment, Macular Degeneration
Interventions
eccentric viewing training with biofeedback
Behavioral
Lead sponsor
New England College of Optometry
Other
Eligibility
14 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 26, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

NCT01736592
View directory record Official record
Conditions
Stargardt's Disease
Interventions
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2033
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 4:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

NCT01402544
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 26, 2026, 4:14 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT05380492
View directory record Official record
Conditions
Age-related Macular Degeneration, Geographic Atrophy
Interventions
VOY-101
Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 26, 2026, 4:14 PM EDT
Recruiting Phase 2 Interventional

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

NCT06557460
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
Surgical implantation of the CPCB-RPE1 implant
Device
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
5
States / cities
Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Lucentis in Advanced Macular Degeneration

NCT00896779
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Steven R. Sanislo
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 26, 2026, 4:14 PM EDT
Terminated Not applicable Interventional

Patient Positioning in Lumbar Fusion Surgery and Its Impact on Spinal Sagittal Balance and Surgeon Satisfaction

NCT01326091
View directory record Official record
Conditions
Intervertebral Disk Degeneration
Interventions
Hyperlordotic Positioning
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Sep 26, 2026, 4:14 PM EDT
Terminated No phase listed Observational

A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02479386
View directory record Official record
Conditions
Geographic Atrophy
Interventions
No intervention
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Springdale, Arkansas • Campbell, California • Glendale, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 26, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Factors in Learning And Plasticity: Healthy Vision

NCT05439759
View directory record Official record
Conditions
Central Visual Impairment, Macular Degeneration
Interventions
Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention, Condition 4: Combination training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 26, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional

Intervention for Communication Quality of Life in Primary Progressive Aphasia

NCT07219680
View directory record Official record
Conditions
Primary Progressive Aphasia(PPA), Semantic Dementia, Logopenic Progressive Aphasia (LPA), Nonfluent Aphasia, Progressive, Progressive Aphasia, Semantic Variant Primary Progressive Aphasia (svPPA), Semantic Aphasia, Logopenic Variant Primary Progressive Aphasia, Logopenic Variant of Primary Progressive Aphasia (LPA), Logopenic Progressive Aphasia, Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Nonfluent Progressive Aphasia
Interventions
Multicomponent Lexical Retrieval Cascade Training, Multicomponent Video Implemented Script Training in Aphasia
Behavioral
Lead sponsor
Maya Henry
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration

NCT00716586
View directory record Official record
Conditions
Retinal Degenerations
Interventions
2% dorzolamide
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 26, 2026, 4:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pistachios and Neural Macular Pigment

NCT05283941
View directory record Official record
Conditions
Macular Degeneration, Retinal Degeneration, Retinal Diseases, Eye Diseases
Interventions
Pistachio Group
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
40 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

NCT03835884
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 26, 2026, 4:14 PM EDT
Terminated Not applicable Interventional

Ascension PyroCarbon Radial Head Study

NCT02405234
View directory record Official record
Conditions
Degenerative Arthritis, Radial Head Fracture, Rheumatoid Arthritis
Interventions
Carbon Modular Radial Head replacement, Metal Radial Head replacement
Device
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
4
States / cities
Gainesville, Florida • Dayton, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia

NCT02506036
View directory record Official record
Conditions
Frontotemporal Dementia, Right Sided Cerebral Hemisphere Cerebrovascular Accident
Interventions
Brain HQ
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 26, 2026, 4:14 PM EDT
Completed No phase listed Observational Results available

A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System

NCT02036931
View directory record Official record
Conditions
Noninflammatory Degenerative Joint Disease, Rheumatoid Arthritis
Interventions
Metal on Polyethylene articulation, Ceramic on Polyethylene articulation, Ceramic on Ceramic articulation
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 26, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 26, 2026, 4:14 PM EDT